BBIO
Neutral signalScored 2026-08-22 Drivers: Congress, fundamentals. Insiders: neutral. Moteurs : Congrès, fondamentaux. Initiés : neutre.
Research, not advice.
À propos
BridgeBio Pharma, Inc.
- Nom
- BridgeBio Pharma, Inc.
- Secteur
- Healthcare
- Industrie
- Biotechnology
- Bourse
- NASDAQ
- Capitalisation
- $13.4B
- Employés
- 999
- PDG
- Neil Kumar
- Site web
- https://www.bridgebio.com
- Marché
- ALNYASNDBMRNDNLIIONSMAZE
BridgeBio Pharma, Inc. is a pharmaceutical company dedicated to identifying, advancing, and providing medical solutions for various genetic conditions. The firm boasts an extensive portfolio comprising 30 distinct development initiatives, spanning the entire spectrum from initial discovery research to advanced clinical trial phases. Notable candidates within its development pipeline include: AG10 and BBP-265: A small molecule designed to stabilize transthyretin (TTR), currently in a pivotal Phase 3 clinical trial targeting transthyretin amyloidosis-cardiomyopathy (ATTR-CM). BBP-831: A selective small molecule inhibitor of FGFR1-3, which is undergoing Phase 2 clinical evaluation for treating achondroplasia in pediatric patients. BBP-631: An AAV5 gene transfer product candidate, also in Phase 2 clinical trials, aimed at congenital adrenal hyperplasia (CAH) caused by 21-hydroxylase deficiency (21OHD). Furthermore, BridgeBio is developing: Encaleret: A small molecule antagonist of the calcium sensing receptor (CaSR), presently in a Phase 2 proof-of-concept study for Autosomal Dominant Hypocalcemia Type 1 (ADH1). BBP-711: Intended for the management of hyperoxaluria and individuals prone to recurring kidney stones. Beyond these specific programs, the company is actively engaged in developing therapies for a broader range of Mendelian disorders, oncological diseases, and gene therapy applications. BridgeBio Pharma, Inc. maintains strategic licensing and collaboration agreements with institutions such as Leland Stanford Junior University, The Regents of the University of California, and Leidos Biomedical Research, Inc. Established in 2015, the company's corporate headquarters are situated in Palo Alto, California.
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
VENTE TOTALE: 200 736 titres (~16 762 110,01 $ US)
- Insiders
- Kumar NeilEllis AndreaCook Jennifer E.
- Total bought
-
—
Avg buy (VWAP, 90d window) —
- Total sold
-
$358,109
Avg sell (VWAP, 90d window) $78.22 vs last close —
Total sold sums Form 4 code S in this window. Codes F, M, A and G are left out.
$358,109 of that total is under a Rule 10b5-1 plan. It is shown here and left out of the score.
- Last activity
- 2026-08-18
- Last synced
-
2026-08-25 17:08:49
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
| Date | Person | Side | Shares | Price | Value | Form 4 |
|---|---|---|---|---|---|---|
| 2026-09-17 | Kumar Neil | Sell · S · 10b5-1 | 1,279 | $69.57 | $88,980 | Form 4 |
| 2026-08-19 | Kumar Neil | Sell · S · 10b5-1 | 100 | $85.65 | $8,565 | Form 4 |
| 2026-08-18 | Kumar Neil | Sell · S · 10b5-1 | 1,199 | $83.77 | $100,444 | Form 4 |
| 2026-07-30 | Apuli Maricel | Sell · S · 10b5-1 | 2,000 | $80.06 | $160,120 | Form 4 |
Sales marked 10b5-1 are scheduled in advance and don't count toward the Quorum score. Les ventes marquées 10b5-1 sont planifiées à l'avance et ne pèsent pas dans le score Quorum.
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
No STOCK Act disclosures for this company in this window.
Recent trades
| Date | Representative | Type | Amount |
|---|---|---|---|
| 2026-05-11 | Gilbert Cisneros | Purchase | $1,001 - $15,000 |
| 2026-04-29 | Gilbert Cisneros | Purchase | $1,001 - $15,000 |
| 2026-03-19 | Gilbert Cisneros | Purchase | $1,001 - $15,000 |
| 2026-03-18 | Gilbert Cisneros | Purchase | $1,001 - $15,000 |
| 2026-03-03 | Gilbert Cisneros | Purchase | $1,001 - $15,000 |
| 2025-09-22 | Gilbert Cisneros | Purchase | $1,001 - $15,000 |
| 2025-08-08 | Gilbert Cisneros | Purchase | $1,001 - $15,000 |
Signal
Neutral signalScored 2026-08-22 Drivers: Congress, fundamentals. Insiders: neutral. Moteurs : Congrès, fondamentaux. Initiés : neutre.
BBIO presents a compelling near-term event-driven opportunity driven by Attruby's strong commercial ramp (sales tripling YoY) and a reaffirmed $1B+ 2026 revenue guidance, supported by a moderately confident catalyst…
The first sentence of the analysis written for BBIO on 2026-08-22 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Unavailable or mixed. – Insider: neutral. All sales (≈ $261K) were pre-planned Rule 10b5-1 trades, excluded from the score. No open-market buys or discretionary sales. – Initiés : neutre. Toutes les ventes (≈ $261K) sont sous plan 10b5-1 préétabli, exclues du score. Aucun achat ni vente discrétionnaire.
- Congress Supports a bullish reading. 5 purchase disclosures year to date
- Narrative Unavailable or mixed. Stored narrative reading is in the neutral band
- Timing Unavailable or mixed. No stored price series
- Financial indicators Unavailable or mixed. Current ratio 2.62 · operating margin -113% — readings disagree
Market snapshot
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 94.4% | 98.3% | 73.7% | 95.6% | 95.5% | |
| Ebit Margin | -135.8% | -199.6% | -6148.1% | -520.6% | -774.1% | |
| Ebitda Margin | -134.0% | -196.9% | -6078.3% | -511.9% | -765.7% | |
| Operating Profit Margin | -113.3% | -267.2% | -6528.8% | -659.6% | -827.1% | |
| Pretax Profit Margin | -146.4% | -244.3% | -7021.9% | -624.2% | -841.2% | |
| Continuous Operations Profit Margin | -146.5% | -244.9% | -7021.9% | -624.2% | -841.2% | |
| Net Profit Margin | -145.3% | -241.4% | -6913.9% | -619.7% | -806.9% | |
| Bottom Line Profit Margin | -145.3% | -241.4% | -6913.9% | -619.7% | -806.9% | |
| Current Ratio | 2.617 | 4.668 | 3.320 | 4.520 | 6.581 | |
| Quick Ratio | 2.524 | 4.668 | 3.320 | 4.520 | 6.581 | |
| Solvency Ratio | -0.239 | -0.223 | -0.337 | -0.254 | -0.296 | |
| Cash Ratio | 1.980 | 4.411 | 2.613 | 3.102 | 2.915 | |
| Price To Earnings Ratio | -20.182 | -9.528 | -10.220 | -2.275 | -4.277 | |
| Price To Earnings Growth Ratio | -0.639 | 0.352 | -0.571 | 0.161 | 0.877 | |
| Forward Price To Earnings Growth Ratio | -0.639 | 0.352 | -0.571 | 0.161 | 0.877 | |
| Price To Earnings Diluted Ratio | -20.182 | -9.528 | -10.220 | -2.275 | -4.277 | |
| Price To Earnings Diluted Growth Ratio | -0.639 | 0.352 | -0.571 | 0.161 | 0.877 | |
| Price To Book Ratio | -7.265 | -3.478 | -4.853 | -0.896 | -2.766 | |
| Price To Sales Ratio | 30.049 | 23.010 | 706.427 | 14.472 | 34.538 | |
| Price To Free Cash Flow Ratio | -33.751 | -9.788 | -12.423 | -2.639 | -4.409 | |
| Price To Operating Cash Flow Ratio | -33.834 | -9.805 | -12.453 | -2.679 | -4.836 | |
| Debt To Assets Ratio | 2.915 | 1.882 | 3.184 | 2.766 | 1.704 | |
| Debt To Equity Ratio | -1.314 | -1.179 | -1.285 | -1.374 | -1.983 | |
| Debt To Capital Ratio | 4.184 | 6.588 | 4.512 | 3.675 | 2.017 | |
| Long Term Debt To Capital Ratio | 4.291 | 6.791 | 4.636 | 3.770 | 2.044 | |
| Financial Leverage Ratio | -0.451 | -0.626 | -0.403 | -0.497 | -1.164 | |
| Working Capital Turnover Ratio | 0.973 | 0.493 | 0.024 | 0.131 | 0.107 | |
| Operating Cash Flow Ratio | -1.548 | -3.373 | -3.669 | -3.455 | -3.687 | |
| Operating Cash Flow Sales Ratio | -0.888 | -2.347 | -56.726 | -5.403 | -7.142 | |
| Free Cash Flow Operating Cash Flow Ratio | 1.002 | 1.002 | 1.002 | 1.015 | 1.097 | |
| Debt Service Coverage Ratio | -9.550 | -4.411 | -6.956 | -4.941 | -11.412 | |
| Interest Coverage Ratio | -10.717 | -5.972 | -7.472 | -6.368 | -12.327 | |
| Short Term Operating Cash Flow Coverage Ratio | -25.608 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Operating Cash Flow Coverage Ratio | -0.163 | -0.301 | -0.303 | -0.243 | -0.288 | |
| Capital Expenditure Coverage Ratio | -406.481 | -558.120 | -404.074 | -66.365 | -10.321 | |
| Dividend Paid And Capex Coverage Ratio | -406.481 | -558.120 | -404.074 | -66.365 | -10.321 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | -25.629 | -14.091 | -14.034 | -6.216 | -7.006 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 94.4% | ▼-3.9% | ▲2.9% |
| Ebit Margin | -135.8% | ▲63.8% | ▲1419.8% |
| Ebitda Margin | -134.0% | ▲62.8% | ▲1403.3% |
| Operating Profit Margin | -113.3% | ▲153.9% | ▲1565.9% |
| Pretax Profit Margin | -146.4% | ▲98.0% | ▲1629.2% |
| Continuous Operations Profit Margin | -146.5% | ▲98.4% | ▲1629.2% |
| Net Profit Margin | -145.3% | ▲96.2% | ▲1600.2% |
| Bottom Line Profit Margin | -145.3% | ▲96.2% | ▲1600.2% |
| Current Ratio | 2.617 | ▼-2.050 | ▼-1.724 |
| Quick Ratio | 2.524 | ▼-2.143 | ▼-1.798 |
| Solvency Ratio | -0.239 | ▼-0.016 | ▲0.031 |
| Cash Ratio | 1.980 | ▼-2.432 | ▼-1.025 |
| Price To Earnings Ratio | -20.182 | ▼-10.654 | ▼-10.886 |
| Price To Earnings Growth Ratio | -0.639 | ▼-0.991 | ▼-0.675 |
| Forward Price To Earnings Growth Ratio | -0.639 | ▼-0.991 | ▼-0.675 |
| Price To Earnings Diluted Ratio | -20.182 | ▼-10.654 | ▼-10.886 |
| Price To Earnings Diluted Growth Ratio | -0.639 | ▼-0.991 | ▼-0.675 |
| Price To Book Ratio | -7.265 | ▼-3.787 | ▼-3.413 |
| Price To Sales Ratio | 30.049 | ▲7.039 | ▼-131.651 |
| Price To Free Cash Flow Ratio | -33.751 | ▼-23.963 | ▼-21.149 |
| Price To Operating Cash Flow Ratio | -33.834 | ▼-24.028 | ▼-21.112 |
| Debt To Assets Ratio | 2.915 | ▲1.033 | ▲0.425 |
| Debt To Equity Ratio | -1.314 | ▼-0.135 | ▲0.113 |
| Debt To Capital Ratio | 4.184 | ▼-2.404 | ▼-0.011 |
| Long Term Debt To Capital Ratio | 4.291 | ▼-2.500 | ▼-0.015 |
| Financial Leverage Ratio | -0.451 | ▲0.175 | ▲0.177 |
| Working Capital Turnover Ratio | 0.973 | ▲0.480 | ▲0.627 |
| Operating Cash Flow Ratio | -1.548 | ▲1.824 | ▲1.598 |
| Operating Cash Flow Sales Ratio | -0.888 | ▲1.458 | ▲13.613 |
| Free Cash Flow Operating Cash Flow Ratio | 1.002 | ▲0.001 | ▼-0.021 |
| Debt Service Coverage Ratio | -9.550 | ▼-5.139 | ▼-2.096 |
| Interest Coverage Ratio | -10.717 | ▼-4.745 | ▼-2.146 |
| Short Term Operating Cash Flow Coverage Ratio | -25.608 | ▼-25.608 | ▼-20.486 |
| Operating Cash Flow Coverage Ratio | -0.163 | ▲0.138 | ▲0.097 |
| Capital Expenditure Coverage Ratio | -406.481 | ▲151.639 | ▼-117.409 |
| Dividend Paid And Capex Coverage Ratio | -406.481 | ▲151.639 | ▼-117.409 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | -25.629 | ▼-11.538 | ▼-12.234 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $15.09B | $5.11B | $6.57B | $1.12B | $2.41B | |
| Enterprise value | $17.25B | $6.16B | $7.94B | $2.47B | $3.74B | |
| EV / Sales | 34.35x | 27.74x | 853.04x | 31.82x | 53.65x | |
| EV / Op. cash flow | -38.67x | -11.82x | -15.04x | -5.89x | -7.51x | |
| EV / Free cash flow | -38.58x | -11.80x | -15.00x | -5.80x | -6.85x | |
| EV / EBITDA | -25.63x | -14.09x | -14.03x | -6.22x | -7.01x | |
| Net debt / EBITDA | -3.21x | -2.40x | -2.41x | -3.39x | -2.50x | |
| Current ratio | 2.62x | 4.67x | 3.32x | 4.52x | 6.58x | |
| Income quality | 0.61x | 0.96x | 0.82x | 0.87x | 0.85x | |
| Graham net-net | -$12 | -$9 | -$9 | -$9 | -$7 | |
| Tax burden | 99.2% | 98.8% | 98.5% | 99.3% | 95.9% | |
| Interest burden | 107.8% | 122.4% | 114.2% | 119.9% | 108.7% | |
| Working capital | $465.7M | $566.3M | $333.7M | $427.4M | $753.8M | |
| Invested capital | $507.3M | $603.0M | $379.9M | $481.4M | $844.7M | |
| Return on assets | -77.9% | -58.3% | -117.7% | -77.2% | -55.5% | |
| Operating ROA | -61.3% | -80.9% | -103.9% | -62.6% | -67.2% | |
| Return on tangible assets | -80.3% | -59.8% | -123.7% | -81.0% | -58.1% | |
| Return on equity | 35.1% | 36.5% | 47.5% | 38.4% | 64.6% | |
| Return on invested capital | -108.5% | -77.1% | -149.4% | -101.4% | -65.3% | |
| Return on capital employed | -87.8% | -77.5% | -150.9% | -102.1% | -65.7% | |
| Earnings yield | -4.8% | -10.5% | -9.8% | -42.8% | -23.4% | |
| Free cash flow yield | -3.0% | -10.2% | -8.0% | -37.9% | -22.7% | |
| Capex / Op. cash flow | -0.2% | -0.2% | -0.2% | -1.5% | -9.7% | |
| Capex / Depreciation | 18.4% | 15.4% | 20.1% | 93.4% | 825.7% | |
| Capex / Sales | 0.2% | 0.4% | 14.0% | 8.1% | 69.2% | |
| SG&A / Sales | 110.6% | 130.2% | 1618.7% | 184.4% | 275.7% | |
| R&D / Sales | 95.1% | 228.2% | 4898.5% | 514.5% | 646.9% | |
| Stock comp / Sales | 26.5% | 43.2% | 0.0% | 117.9% | 142.7% | |
| Intangibles / Total assets | 3.0% | 2.6% | 4.8% | 4.6% | 4.4% | |
| Days sales outstanding | 101d | 8d | 69d | 80d | 103d | |
| Days payables outstanding | 468d | 905d | 1590d | 1228d | 1393d | |
| Operating cycle | 447d | 8d | 69d | 80d | 103d | |
| Cash conversion cycle | -21d | -897d | -1521d | -1148d | -1290d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Change over 5 years
Employee count
Peer market caps
Recent news
- 2026-08-14 BridgeBio Stock Has Soared 29% in Just 3 Months. Here''s Why Wall Street Thinks It Could Go Even Higher. Sales of BridgeBio''s cutting-edge heart drug nearly tripled year over year in the second quarter. The biotech also has other medications in late-stage development that are packed with potential.
- 2026-08-14 BridgeBio Pharma Announces Pricing of Oversubscribed Secondary Offering that Diversifies its Institutional Shareholder Base - The transaction supports the evolution of the Company''s shareholder base toward further high-quality, long-term ownership PALO ALTO, Calif., Aug. 14, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio”), a commercial-stage, multi-product biopharmaceutical company focused on developing medicines for genetic conditions, announced today the pricing of a secondary offering of 5,000,000 shares of its common stock by the selling stockholder KKR Genetic Disorder L.P.
- 2026-08-13 BridgeBio Pharma Announces Launch of Secondary Offering of Common Stock on Behalf of an Existing Shareholder PALO ALTO, Calif., Aug. 13, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio”), a commercial-stage, multi-product biopharmaceutical company focused on developing medicines for genetic conditions, announced today the launch of a secondary public offering of 5,000,000 shares of its common stock by the selling stockholder KKR Genetic Disorder L.P. The Company is not selling any shares and will not receive any of the proceeds of the offering.
- 2026-08-12 BridgeBio Pharma Q2 Earnings Call Highlights BridgeBio Pharma (NASDAQ: BBIO) reported continued growth for its ATTR cardiomyopathy treatment Attruby in the second quarter of 2026, while advancing three late-stage programs into regulatory review and expanding commercial preparations for potential launches over the next year. Chief Executive Officer Neil Kumar described the period as a transition point for the company, citing the commercial
- 2026-08-11 BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) PALO ALTO, Calif., Aug. 11, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing medicines for genetic conditions, today announced that on August 8, 2026, the compensation committee of BridgeBio''s board of directors approved equity grants to 56 new employees in restricted stock units for an aggregate of 66,705 shares of the Company''s common stock. One-fourth of the shares underlying each employee''s restricted stock units will vest on August 16, 2027, with one-twelfth of the remaining shares underlying each such employee''s restricted stock units vesting on a quarterly basis thereafter, in each case, subject to each such employee''s continued employment with the Company or one of its subsidiaries on such vesting dates.
- 2026-08-11 BridgeBio Q2 Earnings Miss, Revenues Beat as Attruby Sales Surge BBIO''s Q2 loss misses estimates, but revenues beat expectations as Attruby sales more than tripled, fueling growth and pipeline advances.
- 2026-08-11 BridgeBio: Attruby Delivers In Q2, Expect Three New Launches In 12 Months BridgeBio (BBIO) delivered a Q2 beat, reaffirmed $1B+ 2026 Attruby/Beyonttra global sales guidance, and expectations for three product launches by mid-2027. Attruby''s U.S. net sales surged 311% Y/Y, with ex-U.S. Beyonttra royalties up 62% sequentially as they continue to gain TTR stabilizer market share. BBIO''s $1B preferred equity raise addresses balance sheet concerns, supporting accelerated commercial and pipeline investment.
- 2026-08-11 4 Biotech Stocks With Major Second-Half Pipeline Catalysts This Year Vertex Pharmaceuticals, Amylyx Pharmaceuticals, Praxis Precision Medicines and BridgeBio Pharma face major 2026 catalysts, from FDA decisions to late-stage readouts.
- 2026-08-10 BridgeBio Pharma, Inc. (BBIO) Q2 2026 Earnings Call Transcript BridgeBio Pharma, Inc. (BBIO) Q2 2026 Earnings Call Transcript
- 2026-08-10 BridgeBio Pharma (BBIO) Reports Q2 Loss, Tops Revenue Estimates BridgeBio Pharma (BBIO) came out with a quarterly loss of $0.78 per share versus the Zacks Consensus Estimate of a loss of $0.64. This compares to a loss of $0.95 per share a year ago.